Description

Rcemic-(5S,9S)-tert-Butyl 2-Oxo-9-Phenyl-1,7-Diazaspiro[4.4]Nonane-7-Carboxylate is a high-value, advanced pharmaceutical intermediate featuring a complex spirocyclic diaza structure. This compound is critical for the synthesis of novel therapeutic agents, particularly in the development of central nervous system (CNS) and protease inhibitor drugs. It is primarily sought after by research institutions, contract development and manufacturing organizations (CDMOs), and pharmaceutical companies engaged in innovative drug discovery and process chemistry.

Application

• Pharmaceutical Intermediate: A key chiral building block in the synthesis of complex active pharmaceutical ingredients (APIs) targeting neurological disorders.
• Drug Discovery Research: Used in medicinal chemistry for structure-activity relationship (SAR) studies and the creation of new chemical entities (NCEs) with spirocyclic scaffolds.
• Protease Inhibitor Development: Serves as a core structural motif in the design and optimization of novel protease inhibitors for antiviral and anticancer therapies.
• Asymmetric Synthesis: Utilized as a precursor or template in stereoselective synthesis to introduce complex molecular architecture.
• Contract Manufacturing: Supplied to CDMOs for scale-up and cGMP production of clinical trial materials and commercial APIs.
• Academic Research: Employed in university and institutional labs for advanced organic methodology development and pharmacological studies.

Basic Information

Product Name	Rcemic-(5S,9S)-tert-Butyl 2-Oxo-9-Phenyl-1,7-Diazaspiro[4.4]Nonane-7-Carboxylate
CAS No.	1251003-15-2
Molecular Formula	C18H24N2O3
Molecular Weight	316.40 g/mol
Synonyms	tert-Butyl 2-oxo-9-phenyl-1,7-diazaspiro[4.4]nonane-7-carboxylate; (±)-(5S,9S)-tert-Butyl 2-oxo-9-phenyl-1,7-diazaspiro[4.4]nonane-7-carboxylate; 1,7-Diazaspiro[4.4]nonane-7-carboxylic acid, 2-oxo-9-phenyl-, 1,1-dimethylethyl ester, (5S,9S)-; 7-Boc-9-phenyl-1,7-diazaspiro[4.4]nonan-2-one; 1251003-15-2; 9-Phenyl-1,7-diazaspiro[4.4]nonane-2-one-7-carboxylic acid tert-butyl ester; Spirocyclic diaza lactam intermediate
EINECS	Contact for details

Quality Control

Our production of Rcemic-(5S,9S)-tert-Butyl 2-Oxo-9-Phenyl-1,7-Diazaspiro[4.4]Nonane-7-Carboxylate adheres to stringent quality management systems, ensuring batch-to-batch consistency for critical research and development applications. Identity, purity, and impurity profiles are verified using advanced analytical techniques including HPLC, GC, NMR, and MS. A comprehensive Certificate of Analysis (COA) detailing all specifications is provided with each shipment to support your regulatory and quality documentation needs.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (15-25°C). The compound may be hygroscopic; keep the container tightly sealed under an inert atmosphere if necessary to maintain stability.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 98.0%
Purity (HPLC, Area %)	≥ 99.0%
Single Maximum Impurity	≤ 0.5%
Total Impurities	≤ 1.0%
Residual Solvents (GC)	Meets ICH Q3C guidelines
Water Content (KF)	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.